Literature DB >> 26939556

Reply to 'Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab'.

L C Olmos1, M S Sayed1, R K Lee1.   

Abstract

Entities:  

Year:  2016        PMID： 26939556      PMCID： PMC4906447          DOI： 10.1038/eye.2016.32

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  10 in total

1.  Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Authors:  Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

2.  Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors:  L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

3.  Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.

Authors:  A L Moraczewski; R K Lee; P F Palmberg; P J Rosenfeld; W J Feuer
Journal:  Br J Ophthalmol       Date:  2008-12-15       Impact factor: 4.638

4.  Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.

Authors:  Aachal Kotecha; Alexander Spratt; Lola Ogunbowale; Roberto dell'Omo; Avinash Kulkarni; Catey Bunce; Wendy A Franks
Journal:  Arch Ophthalmol       Date:  2011-02

5.  Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-04

6.  Reply to 'Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab'.

Authors:  L C Olmos; M S Sayed; R K Lee
Journal:  Eye (Lond)       Date:  2016-03-04       Impact factor: 3.775

7.  Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.

Authors:  Paul M Beer; Susan J Wong; Amjad M Hammad; Naomi S Falk; Martin R O'Malley; Samira Khan
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

8.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

9.  Pharmacokinetics of intravitreal bevacizumab (Avastin).

Authors:  Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Ravinder J Singh
Journal:  Ophthalmology       Date:  2007-05       Impact factor: 12.079

10.  Role of intravitreal bevacizumab in neovascular glaucoma.

Authors:  Moataz E Gheith; Ghada A Siam; Daniela S Monteiro de Barros; Sunir J Garg; Marlene R Moster
Journal:  J Ocul Pharmacol Ther       Date:  2007-10       Impact factor: 2.671
  10 in total
  1 in total

1.  Reply to 'Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab'.

Authors:  L C Olmos; M S Sayed; R K Lee
Journal:  Eye (Lond)       Date:  2016-03-04       Impact factor: 3.775
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.